{"id":"https://openalex.org/W3097315641","doi":"https://doi.org/10.1016/j.bmc.2020.115826","title":"N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay","display_name":"N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay","publication_year":2020,"publication_date":"2020-10-27","ids":{"openalex":"https://openalex.org/W3097315641","doi":"https://doi.org/10.1016/j.bmc.2020.115826","mag":"3097315641","pmid":"https://pubmed.ncbi.nlm.nih.gov/33160146"},"language":"en","primary_location":{"id":"doi:10.1016/j.bmc.2020.115826","doi":"https://doi.org/10.1016/j.bmc.2020.115826","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.bmc.2020.115826","pdf_url":"https://www.sciencedirect.com/science/article/am/pii/S0968089620306568","source":{"id":"https://openalex.org/S10422866","display_name":"Bioorganic & Medicinal Chemistry","issn_l":"0968-0896","issn":["0968-0896","1464-3391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Bioorganic & Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.sciencedirect.com/science/article/am/pii/S0968089620306568","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016050560","display_name":"Takeru Furuya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Takeru Furuya","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA. Electronic address: takeru.furuya@astellas.com","Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA. Electronic address: takeru.furuya@astellas.com","institution_ids":["https://openalex.org/I4210159505"]},{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090436170","display_name":"Adam B. Shapiro","orcid":"https://orcid.org/0000-0002-2662-6146","observed_orcids":["https://orcid.org/0000-0002-2662-6146"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam B. Shapiro","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028192952","display_name":"Janelle Comita-Prevoir","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janelle Comita-Prevoir","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019941262","display_name":"Eric J. Kuenstner","orcid":"https://orcid.org/0000-0003-4094-982X","observed_orcids":["https://orcid.org/0000-0003-4094-982X"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric J. Kuenstner","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100623618","display_name":"Jing Zhang","orcid":"https://orcid.org/0000-0002-2920-909X","observed_orcids":["https://orcid.org/0000-0002-2920-909X"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing Zhang","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026948893","display_name":"Seth D. Ribe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Seth D. Ribe","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035560905","display_name":"April Chen","orcid":"https://orcid.org/0000-0002-0463-2414","observed_orcids":["https://orcid.org/0000-0002-0463-2414"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"April Chen","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040987544","display_name":"Daniel J. Hines","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Hines","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052120675","display_name":"Samir H. Moussa","orcid":"https://orcid.org/0000-0001-5348-596X","observed_orcids":["https://orcid.org/0000-0001-5348-596X"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samir H. Moussa","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008213744","display_name":"Nicole Carter","orcid":"https://orcid.org/0000-0002-3946-8052","observed_orcids":["https://orcid.org/0000-0002-3946-8052"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole M. Carter","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003079010","display_name":"Mark A. Sylvester","orcid":"https://orcid.org/0000-0003-4472-7896","observed_orcids":["https://orcid.org/0000-0003-4472-7896"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. Sylvester","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110802329","display_name":"Jan Antoinette C. Romero","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jan A.C. Romero","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049422638","display_name":"Camilo V. Vega","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Camilo V. Vega","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016545325","display_name":"Michael Dominic Sacco","orcid":"https://orcid.org/0000-0001-5930-7363","observed_orcids":["https://orcid.org/0000-0001-5930-7363"]},"institutions":[{"id":"https://openalex.org/I2613432","display_name":"University of South Florida","ror":"https://ror.org/032db5x82","country_code":"US","type":"education","lineage":["https://openalex.org/I2613432"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael D. Sacco","raw_affiliation_strings":["Department of Molecular Medicine, Morsani College of Medicine, University of South Florida 12901 Bruce B. Downs Blvd, MDC 07, Tampa, FL 33612, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular Medicine, Morsani College of Medicine, University of South Florida 12901 Bruce B. Downs Blvd, MDC 07, Tampa, FL 33612, USA","institution_ids":["https://openalex.org/I2613432"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100402049","display_name":"Yu Chen","orcid":"https://orcid.org/0000-0002-5115-3600","observed_orcids":["https://orcid.org/0000-0002-5115-3600"]},"institutions":[{"id":"https://openalex.org/I2613432","display_name":"University of South Florida","ror":"https://ror.org/032db5x82","country_code":"US","type":"education","lineage":["https://openalex.org/I2613432"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu Chen","raw_affiliation_strings":["Department of Molecular Medicine, Morsani College of Medicine, University of South Florida 12901 Bruce B. Downs Blvd, MDC 07, Tampa, FL 33612, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular Medicine, Morsani College of Medicine, University of South Florida 12901 Bruce B. Downs Blvd, MDC 07, Tampa, FL 33612, USA","institution_ids":["https://openalex.org/I2613432"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101744099","display_name":"John P. O\u2019Donnell","orcid":"https://orcid.org/0000-0001-5502-8738","observed_orcids":["https://orcid.org/0000-0001-5502-8738"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John P. O'Donnell","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044352209","display_name":"Thomas F. Durand-R\u00e9ville","orcid":"https://orcid.org/0000-0002-3494-6422","observed_orcids":["https://orcid.org/0000-0002-3494-6422"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas F. Durand-Reville","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006271408","display_name":"Alita A. Miller","orcid":"https://orcid.org/0000-0002-7110-0493","observed_orcids":["https://orcid.org/0000-0002-7110-0493"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alita A. Miller","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083446220","display_name":"Rub\u00e9n Tommasi","orcid":"https://orcid.org/0000-0002-1573-7422","observed_orcids":["https://orcid.org/0000-0002-1573-7422"]},"institutions":[{"id":"https://openalex.org/I4210159505","display_name":"Entasis Therapeutics (United States)","ror":"https://ror.org/05f9hgh77","country_code":"US","type":"company","lineage":["https://openalex.org/I4210159505"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ruben A. Tommasi","raw_affiliation_strings":["Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA. Electronic address: ruben.tommasi@entasistx.com","Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA. Electronic address: ruben.tommasi@entasistx.com","institution_ids":["https://openalex.org/I4210159505"]},{"raw_affiliation_string":"Entasis Therapeutics, 35 Gatehouse Dr., Waltham, MA 02451, USA","institution_ids":["https://openalex.org/I4210159505"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5016050560","https://openalex.org/A5083446220"],"corresponding_institution_ids":["https://openalex.org/I4210159505"],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":1.0222,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.68184261,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"28","issue":"24","first_page":"115826","last_page":"115826"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T13160","display_name":"Synthesis and Biological Evaluation","score":0.4242999851703644,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T13160","display_name":"Synthesis and Biological Evaluation","score":0.4242999851703644,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":0.14720000326633453,"subfield":{"id":"https://openalex.org/subfields/2726","display_name":"Microbiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10120","display_name":"Bacterial Genetics and Biotechnology","score":0.047200001776218414,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lpxc-inhibitors","display_name":"LpxC inhibitors","score":0.9750000238418579},{"id":"https://openalex.org/keywords/zinc-binding-group","display_name":"zinc-binding groups","score":0.609000027179718},{"id":"https://openalex.org/keywords/lipid-a-biosynthesis","display_name":"lipid A biosynthesis","score":0.9160000085830688},{"id":"https://openalex.org/keywords/gram-negative-bacteria","display_name":"Gram-negative bacteria","score":0.6629999876022339},{"id":"https://openalex.org/keywords/escherichia-coli-infection","display_name":"Escherichia coli infection","score":0.8989999890327454},{"id":"https://openalex.org/keywords/pseudomonas-aeruginosa","display_name":"Pseudomonas aeruginosa","score":0.9860000014305115},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.9210000038146973},{"id":"https://openalex.org/keywords/antihypertensive-effect","display_name":"antihypertensive effect","score":0.7409999966621399},{"id":"https://openalex.org/keywords/hemodynamic-safety","display_name":"hemodynamic safety","score":0.8849999904632568},{"id":"https://openalex.org/keywords/antibiotic-discovery","display_name":"antibiotic discovery","score":0.7509999871253967}],"concepts":[{"id":"https://openalex.org/C2776281265","wikidata":"https://www.wikidata.org/wiki/Q420327","display_name":"Hydroxamic acid","level":2,"score":0.8586592674255371},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.729552149772644},{"id":"https://openalex.org/C547475151","wikidata":"https://www.wikidata.org/wiki/Q25419","display_name":"Escherichia coli","level":3,"score":0.7217909097671509},{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.7056117057800293},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6864517331123352},{"id":"https://openalex.org/C2777637488","wikidata":"https://www.wikidata.org/wiki/Q31856","display_name":"Pseudomonas aeruginosa","level":3,"score":0.6409168243408203},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5865371823310852},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.47976502776145935},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.3360820710659027},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.31510812044143677},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.18585163354873657},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14819905161857605},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000581","descriptor_name":"Amidohydrolases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D000581","descriptor_name":"Amidohydrolases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D001665","descriptor_name":"Binding Sites","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D004926","descriptor_name":"Escherichia coli","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004927","descriptor_name":"Escherichia coli Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004927","descriptor_name":"Escherichia coli Infections","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005559","descriptor_name":"Formamides","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D005559","descriptor_name":"Formamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D005559","descriptor_name":"Formamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005559","descriptor_name":"Formamides","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006439","descriptor_name":"Hemodynamics","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018360","descriptor_name":"Crystallography, X-Ray","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056004","descriptor_name":"Molecular Dynamics Simulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.bmc.2020.115826","doi":"https://doi.org/10.1016/j.bmc.2020.115826","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.bmc.2020.115826","pdf_url":"https://www.sciencedirect.com/science/article/am/pii/S0968089620306568","source":{"id":"https://openalex.org/S10422866","display_name":"Bioorganic & Medicinal Chemistry","issn_l":"0968-0896","issn":["0968-0896","1464-3391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Bioorganic & Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:33160146","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33160146","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1016/j.bmc.2020.115826","doi":"https://doi.org/10.1016/j.bmc.2020.115826","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.bmc.2020.115826","pdf_url":"https://www.sciencedirect.com/science/article/am/pii/S0968089620306568","source":{"id":"https://openalex.org/S10422866","display_name":"Bioorganic & Medicinal Chemistry","issn_l":"0968-0896","issn":["0968-0896","1464-3391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Bioorganic & Medicinal Chemistry","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W611976593","https://openalex.org/W1598844438","https://openalex.org/W1608501828","https://openalex.org/W1983292094","https://openalex.org/W1984678233","https://openalex.org/W1989154905","https://openalex.org/W1991739064","https://openalex.org/W1996449317","https://openalex.org/W2011785871","https://openalex.org/W2012274183","https://openalex.org/W2052156598","https://openalex.org/W2054762986","https://openalex.org/W2094839373","https://openalex.org/W2097236018","https://openalex.org/W2103242123","https://openalex.org/W2103503400","https://openalex.org/W2114197590","https://openalex.org/W2126678004","https://openalex.org/W2131274993","https://openalex.org/W2144081223","https://openalex.org/W2152132247","https://openalex.org/W2155625937","https://openalex.org/W2159211495","https://openalex.org/W2164990328","https://openalex.org/W2402130561","https://openalex.org/W2430388468","https://openalex.org/W2620075194","https://openalex.org/W2959149559","https://openalex.org/W2991330881","https://openalex.org/W2994197950","https://openalex.org/W3037165409","https://openalex.org/W6683114587","https://openalex.org/W7018033056","https://openalex.org/W7073696094"],"related_works":["https://openalex.org/W7172432521","https://openalex.org/W2352133293","https://openalex.org/W1996449317","https://openalex.org/W4389992249","https://openalex.org/W2011785871","https://openalex.org/W2904572108","https://openalex.org/W4385693949","https://openalex.org/W4361267949","https://openalex.org/W2421752393","https://openalex.org/W4238633340"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2020-11-09T00:00:00"}